Innovative
Monoclonal Antibodies
Against Small Molecules
& Transmembrane Proteins
  • Welcome to singular mAb experience
    • About SYnAbs
    • Rat-LOU Monoclonal Antibodies
    • SYnAbs Gender Equality Plan
    • SYnAbs Quality Policy
  • Custom monoclonal antibody development
    • Transmembrane proteins antibodies
    • Carbohydrate-specific antibodies
    • Epigenetic modifications antibodies
    • Therapeutic cytokine antibodies
    • Peptide biomarkers antibodies
    • Infectious diseases antibodies
    • Steroids antibodies
    • Toxin antibodies
  • Primary monoclonal antibodies
    • Anti-DNP irrelevant antibodies
    • Anti-GPCR antibodies
    • Anti-histone epigenetic modification antibodies
    • Anti-MMP9 & IL1B antibodies
    • Isotype control antibodies
    • Anti-His tag antibodies
    • Anti-steroids antibodies
    • Anti-small molecules antibodies
    • Anti-hemoglobin antibodies
  • Secondary monoclonal antibodies
    • Anti-mouse antibodies
    • Anti-rat antibodies
    • Anti-human antibodies
    • Anti-chicken antibodies
    • Anti-rabbit antibodies
  • Immunoaffinity columns
  • SynAbs recent news
    • GPCR therapeutic monoclonal antibodies
    • Ion channel therapeutic monoclonal antibodies
    • Monoclonal antibody targeting virus envelope
    • Epigenetics and Monoclonal histone modification antibodies
    • Anti-Drug Antibody (ADA) generation
    • Anti-small molecule hapten antibodies
    • Recombinant antibodies
    • Secondary monoclonal antibodies
    • New primary monoclonal antibodies
    • Microbiome, Cell & Gene Therapy
    • Receptor tyrosine kinase therapeutic monoclonal antibodies
    • Immunoglobulin SuperFamily (IgSF) therapeutic antibodies
  • Contact SynAbs
    • Glossary and Frequently Asked Questions

    SYnAbs S.A.

    Rue Auguste Piccard, 48

    I-Tech Incubator 2

    B-6041 Gosselies

    Belgium

    BE 0637.716.206

     

    Follow us on

    Ask for more information


    About | Privacy Policy | Cookie Policy | Sitemap
    Log out | Edit
    • Scroll to top